These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 23953622)

  • 1. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-inflammatory drugs in the 21st century.
    Rainsford KD
    Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
    Konishi H; Yoshikawa T
    Nihon Rinsho; 2011 Jun; 69(6):1110-5. PubMed ID: 21688637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
    Sostres C; Gargallo CJ; Arroyo MT; Lanas A
    Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):121-32. PubMed ID: 20227026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain.
    Sciulli MG; Capone ML; Tacconelli S; Patrignani P
    Pharmacol Rep; 2005; 57 Suppl():66-85. PubMed ID: 16415488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic tools to tailor cancer prevention by NSAIDs.
    Ulrich CM; Bigler J; Potter JD
    Discov Med; 2006 Apr; 6(32):71-4. PubMed ID: 17234129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
    Radi ZA; Khan NK
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the adverse effects of nonsteroidal anti-inflammatory drugs.
    Patrignani P; Tacconelli S; Bruno A; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):605-21. PubMed ID: 22114888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population.
    Capone ML; Tacconelli S; Rodriguez LG; Patrignani P
    Pharmacol Rep; 2010; 62(3):530-5. PubMed ID: 20631418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
    Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
    Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.